Most studies describe an inflammasome-independent role of AIM2 in suppressing tumor growth, such as in colorectal cancer [471, 472, 477–480], breast cancer [487–490], cervical carcinoma [484], gastric cancer [485], hepatocellular carcinoma [491, 492], osteosarcoma [486], and renal carcinoma [481–483]. Here, AIM2 is linked to hepatocellular carcinoma.